Capsule APREPITANT 125 MG – 80MG
|Generic Name of Product||Brand Name||Dosage Form||Strength||Pharmacologic Group||Therapeutic Group||Unit Per Pack|
|Aprepitant||Emexir®||Capsule||80 mg + 80 mg + 125 mg||Neurokinin -receptor antagonist, Antiemetic||Gastrointestinal agents|
Indications And Usage
Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.
Aprepitant 125 mg/80 mg is given as part of combination therapy
The hard capsule should be swallowed whole. Aprepitant may be taken with or without food
Hypersensitivity to the active substance or to any of the excipients. with pimozide, terfenadine, astemizole or cisapride.
Aprepitant should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.
Tiredness, hiccups, nausea, vomiting, heartburn, stomach pain, diarrhea, constipation, loss of appetite, hair loss, headache, dizziness, mild skin rash, ringing in your ears, sleep problems (insomnia).
Pregnancy and lactation
For aprepitant no clinical data on exposed pregnancies are available
aprepitant should not be used during pregnancy unless clearly necessary.
Aprepitant is excreted in the milk of lactating rats.
Renal and liver Impairment
There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. Aprepitant should be used with caution in these patients